Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Can drugs or micronutrients prevent cataract?
Autore:
Harding, JJ;
Indirizzi:
Univ Oxford, Nuffield Lab Ophthalmol, Oxford OX2 6AW, England Univ OxfordOxford England OX2 6AW b Ophthalmol, Oxford OX2 6AW, England
Titolo Testata:
DRUGS & AGING
fascicolo: 7, volume: 18, anno: 2001,
pagine: 473 - 486
SICI:
1170-229X(2001)18:7<473:CDOMPC>2.0.ZU;2-T
Fonte:
ISI
Lingua:
ENG
Soggetto:
ALDOSE REDUCTASE INHIBITORS; NAPHTHALENE-INDUCED CATARACT; AGE-RELATED CATARACTS; MODELING CORTICAL CATARACTOGENESIS; NON-ENZYMIC GLYCOSYLATION; ASPIRIN-LIKE ANALGESICS; RAY-INDUCED CATARACT; BLUE MOUNTAINS EYE; BEAVER DAM EYE; LENS PROTEINS;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
131
Recensione:
Indirizzi per estratti:
Indirizzo: Harding, JJ Univ Oxford, Nuffield Lab Ophthalmol, Walton St, Oxford OX2 6AW, England Univ Oxford Walton St Oxford England OX2 6AW OX2 6AW, England
Citazione:
J.J. Harding, "Can drugs or micronutrients prevent cataract?", DRUG AGING, 18(7), 2001, pp. 473-486

Abstract

Cataract is the major cause of blindness and of visual impairment worldwide, so its prevention is of the greatest importance. At present no drug therapy is licensed for use in the UK or the US, so the only treatment for cataract is by surgery, which is expensive and has adverse effects. This article reviews research on prevention of cataract by a variety of agents, including micronutrients as well as drugs. Benefits have been claimedfor many compounds or mixtures and this review concentrates on those most extensively studied. Information on possible benefits of putative anticataract agents comes from a variety of approaches, from laboratory experiments, both in vitro and in vivo, to epidemiological studies in patients. Sorbitol-lowering drugs were the first to be examined systematically and progressed to clinical trials which were disappointing, and now the entire rationale for their use in prevention of cataract is questionable. Micronutrients showed little promise in animals but came to clinical trial in patients with cataract without the publication of any major benefit. Pantethine showed more promise in animal studies but the only clinical trial was abandoned early. A variety of laboratory and epidemiological evidence supports the benefits of aspirin-like drugs but there has been no trial specifically in patients with cataract. Add-on studies to trials of aspirin for other indications have not been encouraging. Research into other compounds is interesting but less advanced.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 12/07/20 alle ore 06:02:37